Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3256932 | Clinical Immunology | 2013 | 7 Pages |
Therapeutic targeting of proinflammatory cytokines is clinically beneficial in several autoimmune disorders. Several of these cytokines are directly implicated in the pathogenesis of type 1 diabetes, suggesting opportunities for design of clinical trials in type 1 diabetes that incorporate selective cytokine blockade as a component of preventative or interventional immunotherapy. The rationale and status of inhibitory therapy directed against IL-1, TNF, IL-12, IL-23, and IL-6 are discussed, towards a goal of using cytokine inhibition as a therapeutic platform to establish an in vivo milieu suitable for modulating the immune response in T1D.
► Cytokine inhibition supports regulatory immunological mechanisms. ► Cytokines influence immunologic determinism in tissue microenvironments. ► Cytokine blockade can establish a foundation for antigen-specific therapy. ► Several cytokine inhibitors should be evaluated in T1D clinical trials.